title: Long-term results and prognostic factors of patients with cervical carcinoma treated with concurrent chemoradiotherapy.
abstract: OBJECTIVE
  To evaluate the predictive factors of recurrence in cervical cancer treated with radical radiochemotherapy.
  
  
  METHODS
  A retrospective analysis of 56 women was performed. Response was assessed using the RECIST response. Overall survival and disease-free survival curves were estimated by the Kaplan-Meier method and the Cox proportional hazards model was used to analyse predictors of recurrence.
  
  
  RESULTS
  Local recurrence was documented in 16 patients and distant metastases in 15. The Kaplan-Meier survival probabilities were 95.1 ± 6.4% at 3 years and 80.4 ± 13.1% at 5 years and the Kaplan-Meier curve values for disease-free survival were 60.3 ± 14.3% at 3 years and 53.0 ± 15.7% at 5 years. Thirty-five patients were alive and 21 patients died, 19 from metastatic disease and 2 from other causes. Complete response after chemoradiation therapy, squamous cell carcinoma and tumour size ≤ 4 cm were significantly associated with outcome. In the Cox regression model, tumour size > 4 cm (hazard ratio 7.48; 95% CI 2.71-20.6; p < 0.001) and partial response (hazard ratio 7.09; 95% CI 2.82-17.8; p < 0.001) were predictive factors for disease-free survival and partial response (hazard ratio 3.7; 95% CI 1.3-10.1; p < 0.001) and non-squamous cell carcinoma (hazard ratio 3.5; 95% CI 1.2-9.7; p < 0.001) were predictive factors for overall survival.
  
  
  CONCLUSIONS
  Non-squamous histology and partial response were independent prognostic factors for overall survival and tumour size and partial response were independent prognostic variables for 5-year disease survival.
authors.affiliation: Department of Radiation Oncology, Hospital de l'Esperança, IMAS, Barcelona, Spain. areig@parcdesalutmar.cat
authors.forename: Ana
authors.initials: A
authors.lastname: Reig
authors.forename: Ismael
authors.initials: I
authors.lastname: Membrive
authors.forename: Palmira
authors.initials: P
authors.lastname: Foro
authors.forename: Xavier
authors.initials: X
authors.lastname: Sanz
authors.forename: Núria
authors.initials: N
authors.lastname: Rodríguez
authors.forename: Joan
authors.initials: J
authors.lastname: Lozano
authors.forename: Martí
authors.initials: M
authors.lastname: Lacruz
authors.forename: Jaume
authors.initials: J
authors.lastname: Quera
authors.forename: Enric
authors.initials: E
authors.lastname: Fernández-Velilla
authors.forename: Manuel
authors.initials: M
authors.lastname: Algara
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*